# Recombinant SeV-hFGF2/dF Injection for PAOD

> **NCT03668353** · PHASE1 · UNKNOWN · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- PAOD - Peripheral Arterial Occlusive Disease
- PAD
- Critical Limb Ischemia

## Interventions

- **BIOLOGICAL:** Recombinant SeV-hFGF2/dF Injection

## Key facts

- **NCT ID:** NCT03668353
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-05
- **Primary completion:** 2020-03-05
- **Final completion:** 2020-09-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03668353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03668353, "Recombinant SeV-hFGF2/dF Injection for PAOD". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03668353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*